PICP和ICTP诊断前列腺癌骨转移的价值

Evaluation of PICP and ICTP in diagnosis of bone metastasis in prostate cancer

目的研究血清Ⅰ型前胶原羧端肽原（ＰＩＣＰ）和Ⅰ型胶原吡啶交联终肽（ＩＣＴＰ）浓度与前列腺癌骨转移的关系。方法放免法检测６１例ＢＰＨ、１８例前列腺癌和２８例前列腺癌骨转移患者的血清ＰＩＣＰ和ＩＣＴＰ。结果前列腺癌骨转移者的ＰＩＣＰ和ＩＣＴＰ明显升高，ＰＩＣＰ和ＩＣＴＰ联合试验的敏感性和特异性均优于ＰＩＣＰ或ＩＣＴＰ的单独试验。结论ＰＩＣＰ＞２０５μｇ／Ｌ或者ＩＣＴＰ＞６．０μｇ／Ｌ时，应怀疑前列腺癌骨转移；ＰＩＣＰ＞２０５μｇ／Ｌ而且ＩＣＴＰ＞６．０μｇ／Ｌ时，临床诊断前列腺癌骨转移。

Objective To study the correlation between PICP or ICTP and bone metastasis in prostate cancer. Methods Serum levels of PICP and ICTP were measured by radioimmunoassay in 61 patients with benigh prostatic hyperplasia(BPH), 18 patients with prostate cancer and in 28 patients with prostate cancer and bone metastasis. Results The serum levels of PICP and ICTP are significantly increased. The parallel test and serial test are sensitively and specifically higher than the test of either PICP or ICTP. Conclusions When the level of either PICP is more than 205 μg/L or ICTP more than 6.0μg/L, the possibility of bone metastasis should not be neglected. When the level of PICP is above 205 μg/L and that of ICTP above 6.0μg/L, the diagnosis of prostate cancer with bone metastasis is certain.